Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK, Exelixis co-develop, -promote therapeutics; terminated

Executive Summary

Exelixis (genomics-based drug discovery) and GlaxoSmithKline will collaborate for six years to discover, develop, and market drugs with indications in vascular biology, inflammatory diseases, and cancer.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register